Triclabendazole

Summary

Triclabendazole (CHEMBL1086440) is an approved small molecule (ATC P02BX04); indicated across 2 conditions including fascioliasis and helminthiasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P02BX04
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 359.7 Da · C14H9Cl3N2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1086440
Name	Triclabendazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	50248
ATC	P02BX04
Molecular formula	C14H9Cl3N2OS
Molecular weight	359.7
InChIKey	NQPDXQQQCQDHHW-UHFFFAOYSA-N

SMILES: CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl

IUPAC name: 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole

Also known as: EGA230B, Egaten, Egaten tm, Fasinex, NSC-759250, NVP-EGA230, Triclabendazol, Triclabendazole, triclabendazole, SID26719864, SID26758032, SID49681760

Patent coverage: 1,132 distinct patent families (4,136 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 4,044 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Microtubule-associated protein tau, Streptokinase A, Nuclear receptor ROR-gamma, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, Menin/Histone-lysine N-methyltransferase MLL, Transthyretin, Cruzipain, Heat shock protein HSP 90-alpha, Neuropeptide S receptor.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P10520	5.53	EC50	2925	nM	CHEMBL_ACT_4929573
TTR	5.46	IC50	3500	nM	CHEMBL_ACT_23263032
HSP90AA1	5.37	AC50	4247	nM	CHEMBL_ACT_7453974
P10520	5.33	EC50	4695	nM	CHEMBL_ACT_4994653
MAPT	5.1	Potency	7943	nM	CHEMBL_ACT_3973590
MEN1	5	Potency	10000	nM	CHEMBL_ACT_4574866

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
fascioliasis	4	MONDO:0004668	EFO:1001324
helminthiasis	4	MONDO:0004664	EFO:1001342

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06367361	PHASE2	NOT_YET_RECRUITING	One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
NCT01931085	Not specified	NO_LONGER_AVAILABLE	Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).